Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MNOV said it will discontinue development of MN-305 for insomnia after the compound missed the primary endpoint
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury